Active substance
Benazepril
- SFDA 3
- US FDA 14
- Health Canada 3
- US price lines 4
- Safety 3
SFDA Saudi Arabia — SFDA human drug list
| Trade name | Strength | Form · route | Pack | Public price | Type | Company | Status |
|---|---|---|---|---|---|---|---|
| CIBACEN 10MG F.C.TAB | 10 mg | Film-coated tablet · Oral use | 14 Blister | SAR 34.85 | NCE · Prescription | NOVARTIS | Withdrawn by MAH · Not Marketed |
| CIBACEN 20MG F.C.TAB | 20 mg | Film-coated tablet · Oral use | 14 Blister | SAR 57.25 | NCE · Prescription | NOVARTIS | Withdrawn by MAH · Not Marketed |
| CIBACEN 5MG F.C.TAB | 5 mg | Film-coated tablet · Oral use | 14 Blister | SAR 21.05 | NCE · Prescription | NOVARTIS | Withdrawn by MAH · Not Marketed |
US FDA United States — FDA approvals (Drugs@FDA)
| Product | Strength | Form · route | Applicant | Status | First approved |
|---|---|---|---|---|---|
| LOTENSIN | 10MG; 20MG; 40MG | tablet · oral | VALIDUS PHARMS | Prescription | 25 Jun 1991 |
| BENAZEPRIL HYDROCHLORIDE | 5MG; 10MG; 20MG; 40MG | tablet · oral | PRINSTON INC | Prescription | 11 Feb 2004 |
| BENAZEPRIL HYDROCHLORIDE | 5MG; 10MG; 20MG; 40MG | tablet · oral | TEVA | Prescription | 11 Feb 2004 |
| BENAZEPRIL HYDROCHLORIDE | 5MG; 10MG; 20MG; 40MG | tablet · oral | HERITAGE PHARMA | Prescription | 11 Feb 2004 |
| BENAZEPRIL HYDROCHLORIDE | 5MG; 10MG; 20MG; 40MG | tablet · oral | ANI PHARMS | Prescription | 11 Feb 2004 |
| BENAZEPRIL HYDROCHLORIDE | 5MG; 10MG; 20MG; 40MG | tablet · oral | SUN PHARM INDS LTD | Prescription | 11 Feb 2004 |
| BENAZEPRIL HYDROCHLORIDE | 5MG; 10MG; 20MG; 40MG | tablet · oral | CHARTWELL RX | Prescription | 11 Feb 2004 |
| BENAZEPRIL HYDROCHLORIDE | 5MG; 10MG; 20MG; 40MG | tablet · oral | AMNEAL PHARMS | Prescription | 3 Feb 2006 |
| BENAZEPRIL HYDROCHLORIDE | 5MG; 10MG; 20MG; 40MG | tablet · oral | COREPHARMA | Prescription | 8 Mar 2006 |
| BENAZEPRIL HYDROCHLORIDE | 10MG; 20MG; 40MG | tablet · oral | AUROBINDO PHARMA | Prescription | 22 May 2008 |
| BENAZEPRIL HYDROCHLORIDE | 5MG; 10MG; 20MG; 40MG | tablet · oral | ZYDUS LIFESCIENCES | Prescription | 23 May 2008 |
| LOTENSIN | 5MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | tablet · oral | VALIDUS PHARMS | Discontinued | 25 Jun 1991 |
| BENAZEPRIL HYDROCHLORIDE | 5MG; 10MG; 20MG; 40MG | tablet · oral | RISING | Discontinued | 11 Feb 2004 |
| BENAZEPRIL HYDROCHLORIDE | 5MG; 10MG; 20MG; 40MG | tablet · oral | GENPHARM | Discontinued | 11 Feb 2004 |
Canada Canada — marketed products (Health Canada)
| Brand | DIN | Strength | Form · route | Company |
|---|---|---|---|---|
| BENAZEPRIL | 02273918 | 20 MG | TABLET · ORAL | AA PHARMA INC |
| BENAZEPRIL | 02290332 | 5 MG | TABLET · ORAL | AA PHARMA INC |
| BENAZEPRIL | 02290340 | 10 MG | TABLET · ORAL | AA PHARMA INC |
Prices — United States and England
| Source | Product as listed | Price | Unit / pack | Date |
|---|---|---|---|---|
| US NADAC | BENAZEPRIL HCL 10 MG TABLET | $0.06515 | per EA | 23 Sep 2026 |
| US NADAC | BENAZEPRIL HCL 20 MG TABLET | $0.07888 | per EA | 23 Sep 2026 |
| US NADAC | BENAZEPRIL HCL 40 MG TABLET | $0.10107 | per EA | 23 Sep 2026 |
| US NADAC | BENAZEPRIL HCL 5 MG TABLET | $0.04842 | per EA | 23 Sep 2026 |
NADAC: average price US retail pharmacies pay to buy the medicine. NHS Drug Tariff Part VIIIA: basic price reimbursed to pharmacies in England and Wales.
Safety signals and safety-related labeling changes
- US FDA 20 Aug 2020 LOTENSIN HCT — safety-related labeling change
Labeling sections changed: Contraindications; Warnings and Precautions; Adverse Reactions - US FDA 10 Feb 2020 LOTREL — safety-related labeling change
Labeling sections changed: Contraindications; Warnings and Precautions; Drug Interactions; Use in Specific Populations; Patient Counseling Information / Patient Information / Medication Guide - US FDA 7 Jan 2019 LOTENSIN — safety-related labeling change
Labeling sections changed: Contraindications; Warnings and Precautions; Drug Interactions; Use in Specific Populations
Values as published by each source: SFDA human drug list (4-2026, as published by the Council of Health Insurance; indications from the CHI Daman Drug Formulary), Drugs@FDA, EMA medicines data, Health Canada Drug Product Database (Open Government Licence – Canada), CMS NADAC, NHS Drug Tariff Part VIIIA (NHSBSA Copyright, Open Government Licence v3.0), WHO Model List of Essential Medicines (CC BY 3.0 IGO; regrouped by active substance, not created by WHO), EMA PRAC, US FDA safety-related labeling changes and MHRA Drug Safety Update (Open Government Licence v3.0). Sources and reuse. Not a substitute for the official registers or the product information.